Ann: Final Preparations for ATL1103 Clinical Tria, page-32

re: Ann: Final Preparations for ATL1103 Clini... Interesting to see Pattersons has become a big buyer over the last week (they were subunderwriters for the recent capital raising where there was a very large shortfall). Clearly they have told their clients their overhang is gone, and this can return to fair value 1.2/1.4 cents.

Given the imminient approval of human trials for ATL1103, you could argue it deserves to be closer to 2 cents given what it's enterprize value did when it went through the same process with ATL1102.

So happy to pick up stock 0.9 cents, if you are very lucky you might get some at 0.8 cents, but 0.9 cents is the price for worthwhile volume.

GL